Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xiangyi Meng

Showing results (51-60 of 135) with videos related to

Pageof 14
Sort By:
CNS Neuroscience & Therapeutics|October 19, 2010
Efficacy of rivastigmine on executive function in patients with Parkinson's disease dementiaFrederick A Schmitt, Martin R Farlow, Xiangyi Meng, et al.
International Journal of Geriatric Psychiatry|February 12, 2011
Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analysesGustavo Alva, George T Grossberg, Frederick A Schmitt, et al.
American Journal of Hypertension|June 26, 2007
Time to achieve blood-pressure goal: influence of dose of valsartan monotherapy and valsartan and hydrochlorothiazide combination therapyMatthew R Weir, Drew Levy, Nora Crikelair, et al.
CNS Neuroscience & Therapeutics|August 9, 2013
A 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg/24 h versus 4.6 mg/24 h in severe Alzheimer's dementiaMartin R Farlow, George T Grossberg, Carl H Sadowsky, et al.
Advances in Therapy|September 24, 2014
Efficacy and safety of fingolimod in Hispanic patients with multiple sclerosis: pooled clinical trial analysesAngel R Chinea Martinez, Jorge Correale, Patricia K Coyle, et al.
Clinical Drug Investigation|December 10, 2009
Rivastigmine transdermal patch skin tolerability: results of a 1-year clinical trial in patients with mild-to-moderate Alzheimer's diseaseJeffrey L Cummings, Martin R Farlow, Xiangyi Meng, et al.
Nature Communications|November 3, 2023
The nature and nurture of network evolutionBin Zhou, Petter Holme, Zaiwu Gong, et al.
Advanced Materials (Deerfield Beach, Fla.)|July 25, 2017
High Efficiency Nonfullerene Polymer Solar Cells with Thick Active Layer and Large AreaBing Guo, Wanbin Li, Xia Guo, et al.
Primary Care Companion to the Journal of Clinical Psychiatry|September 13, 2008
Safety and efficacy of rivastigmine in patients with Alzheimer's disease not responding adequately to donepezil: an open-label studyGary S Figiel, Carl H Sadowsky, John Strigas, et al.
CNS Neuroscience & Therapeutics|February 14, 2015
Evaluating Response to High-Dose 13.3 mg/24 h Rivastigmine Patch in Patients with Severe Alzheimer's DiseaseMartin R Farlow, Carl H Sadowsky, Drew M Velting, et al.
Pageof 14

Showing results (51-60 of 135) with videos related to

Sort By:
Pageof 14
CNS Neuroscience & Therapeutics|October 19, 2010
Efficacy of rivastigmine on executive function in patients with Parkinson's disease dementiaFrederick A Schmitt, Martin R Farlow, Xiangyi Meng, et al.
International Journal of Geriatric Psychiatry|February 12, 2011
Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analysesGustavo Alva, George T Grossberg, Frederick A Schmitt, et al.
American Journal of Hypertension|June 26, 2007
Time to achieve blood-pressure goal: influence of dose of valsartan monotherapy and valsartan and hydrochlorothiazide combination therapyMatthew R Weir, Drew Levy, Nora Crikelair, et al.
CNS Neuroscience & Therapeutics|August 9, 2013
A 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg/24 h versus 4.6 mg/24 h in severe Alzheimer's dementiaMartin R Farlow, George T Grossberg, Carl H Sadowsky, et al.
Advances in Therapy|September 24, 2014
Efficacy and safety of fingolimod in Hispanic patients with multiple sclerosis: pooled clinical trial analysesAngel R Chinea Martinez, Jorge Correale, Patricia K Coyle, et al.
Clinical Drug Investigation|December 10, 2009
Rivastigmine transdermal patch skin tolerability: results of a 1-year clinical trial in patients with mild-to-moderate Alzheimer's diseaseJeffrey L Cummings, Martin R Farlow, Xiangyi Meng, et al.
Nature Communications|November 3, 2023
The nature and nurture of network evolutionBin Zhou, Petter Holme, Zaiwu Gong, et al.
Advanced Materials (Deerfield Beach, Fla.)|July 25, 2017
High Efficiency Nonfullerene Polymer Solar Cells with Thick Active Layer and Large AreaBing Guo, Wanbin Li, Xia Guo, et al.
Primary Care Companion to the Journal of Clinical Psychiatry|September 13, 2008
Safety and efficacy of rivastigmine in patients with Alzheimer's disease not responding adequately to donepezil: an open-label studyGary S Figiel, Carl H Sadowsky, John Strigas, et al.
CNS Neuroscience & Therapeutics|February 14, 2015
Evaluating Response to High-Dose 13.3 mg/24 h Rivastigmine Patch in Patients with Severe Alzheimer's DiseaseMartin R Farlow, Carl H Sadowsky, Drew M Velting, et al.
Pageof 14